Entera Health Presents Possible New IBS Therapy

At the Experimental Biology 2013 meeting held in Boston April 20 to 24, Entera Health presented nonclinical studies demonstrating oral serum-derived bovine immunoglobulin/protein isolate (SBI) as a promising treatment for irritable bowel syndrome.

Advertisement

Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!

SBI promotes bone density and lean body mass growth, allowing for increased nutrient absorption.

Entera Health is a biotherapeutics company focused on developing treatments for gastroenterology, oncology and immune disorder conditions.

More Articles on Gastroenterology:
Innotex Receives Patent for Colon Cancer Suturing System
Heartland Regional Medical Center Opens Gastroenterology & Hepatology Clinic
Ferring Pharmaceuticals Launches Colon Cancer Awareness Campaign

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.